The KEYNOTE‐189 study reported that the combination of pembrolizumab and platinum drugs prolonged the PFS of patients with metastatic NSCLC by 3.7 months and improved the 10.5‐month OS from 49.4% to 69.2% compared with placebo and platinum drugs [38], but the greatest benefit of this regimen was still in patients with a PD‐L1‐positive rate greater than 50%. Here, CD274 is linked to non-small cell lung carcinoma.